Nuria Carrillo-Carrasco

Nuria Carrillo-Carrasco

Auto-generated profile, based on publicly available information

Nuria Carrillo-Carrasco

Organic Acid Research Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Building 49, Room 4A18, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RCRandy J. Chandler
Randy J. Chandler
MLMatthew C. LaFave
Matthew C. LaFave
GVGaurav K. Varshney
Gaurav K. Varshney
NTNiraj S. Trivedi
Niraj S. Trivedi
NCNuria Carrillo-Carrasco
Nuria Carrillo-Carrasco
CVCharles P. Venditti
Charles P. Venditti
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number of clinical trials. However, the safety of AAV as a vector has been challenged by a single study that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. Most studies have not noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is an association between AAV and HCC is controversial. Here, we performed a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the RNA imprinted and accumulated in nucleus (Rian) locus, and the resulting overexpression of proximal microRNAs and retrotransposon-like 1 (Rtl1) were associated with HCC. In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the timing of gene delivery are all critical factors for determining HCC incidence after AAV gene delivery. Together, our results define aspects of AAV-mediated gene therapy that influence genotoxicity and suggest that these features should be considered for design of both safer AAV vectors and gene therapy studies.

1 August 2003 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
IBIngeborg Becker
Ingeborg Becker
NSNorma Salaiza
Norma Salaiza
MAMagdalena Aguirre
Magdalena Aguirre
JDJose Delgado-Dominguez
Jose Delgado-Dominguez
NCNuria Carrillo-Carrasco
Nuria Carrillo-Carrasco
AIArmando Isibasi
Armando Isibasi

12 July 2011 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
NCNuria Carrillo‐Carrasco
Nuria Carrillo‐Carrasco
RCRandy J. Chandler
Randy J. Chandler
CVCharles P. Venditti
Charles P. Venditti

7 July 2014 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
INIchizo Nishino
Ichizo Nishino
NCNuria Carrillo-Carrasco
Nuria Carrillo-Carrasco
ZAZohar Argov
Zohar Argov
GNE myopathy is an autosomal recessive muscle disease caused by biallelic mutations in GNE, a gene encoding for a single protein with key enzymatic activities, UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase, in sialic acid biosynthetic pathway. The diagnosis should be considered primarily in patients presenting with distal weakness (foot drop) in early adulthood (other onset symptoms are possible too). The disease slowly progresses to involve other lower and upper extremities’ muscles, with marked sparing of the quadriceps. Characteristic findings on biopsies of affected muscles include ‘rimmed’ (autophagic) vacuoles, aggregation of various proteins and fibre size variation. The diagnosis is confirmed by sequencing of the GNE gene. Note that we use a new mutation nomenclature based on the longest transcript (GenBank: NM_001128227), which encodes a 31-amino acid longer protein than the originally described one (GenBank: NM_005476), which has been used previously in most papers. Based upon the pathophysiology of the disease, recent clinical trials as well as early gene therapy trials have evaluated the use of sialic acid or N-acetylmannosamine (a precursor of sialic acid) in patients with GNE myopathy. Now that therapies are under investigation, it is critical that a timely and accurate diagnosis is made in patients with GNE myopathy.

31 January 2014 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
EOElizabeth A. Ottinger
Elizabeth A. Ottinger
MKMark L. Kao
Mark L. Kao
NCNuria Carrillo-Carrasco
Nuria Carrillo-Carrasco
NYNicole Yanjanin
Nicole Yanjanin
RSRoopa Kanakatti Shankar
Roopa Kanakatti Shankar
JMJohn C. McKew
John C. McKew
In 2010, the National Institutes of Health (NIH) established the Therapeutics for Rare and Neglected Diseases (TRND) program within the National Center for Advancing Translational Sciences (NCATS), which was created to stimulate drug discovery and development for rare and neglected tropical diseases through a collaborative model between the NIH, academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies. This paper describes one of the first TRND programs, the development of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for the treatment of Niemann-Pick disease type C1 (NPC1). NPC is a neurodegenerative, autosomal recessive rare disease caused by a mutation in either the NPC1 (about 95% of cases) or the NPC2 gene (about 5% of cases). These mutations affect the intracellular trafficking of cholesterol and other lipids, which leads to a progressive accumulation of unesterified cholesterol and glycosphingolipids in the CNS and visceral organs. Affected individuals typically exhibit ataxia, swallowing problems, seizures, and progressive impairment of motor and intellectual function in early childhood, and usually die in adolescence. There is no disease modifying therapy currently approved for NPC1 in the US. A collaborative drug development program has been established between TRND, public and private partners that has completed the pre-clinical development of HP-β-CD through IND filing for the current Phase I clinical trial that is underway. Here we discuss how this collaborative effort helped to overcome scientific, clinical and financial challenges facing the development of new drug treatments for rare and neglected diseases, and how it will incentivize the commercialization of HP-β-CD for the benefit of the NPC patient community.

2 May 2014 in Human Mutation
Verified
Journal Article
Closed access
PDF file
FCFrank Celeste
Frank Celeste
TVThierry Vilboux
Thierry Vilboux
CCCarla Ciccone
Carla Ciccone
JDJohn Karl de Dios
John Karl de Dios
MMMay Christine V. Malicdan
May Christine V. Malicdan
MHMarjan Huizing
Marjan Huizing